Physician profile
Karen C Keough
NPI 1538147707
$473,963.60
in general payments reported to CMS, 2019-2025
50 companies · $98K in 2025
The $98K reported for 2025 was more than what 99% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $25K · 2021: $30K · 2022: $71K · 2023: $95K · 2024: $113K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $156K · Honoraria: $75K · Travel and Lodging: $35K · Consulting Fee: $25K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,181.00 |
| Honoraria | $75,111.00 |
| Travel and Lodging | $34,850.13 |
| Consulting Fee | $24,968.21 |
| Food and Beverage | $13,386.01 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,656.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $147,752.11 | 2022-2025 | |
| Sk Life Science, INC. | $96,367.33 | 2020-2025 | Xcopri |
| Ucb, INC. | $70,492.13 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Greenwich Biosciences, INC. | $64,906.20 | 2019-2021 | |
| Livanova USA, INC. | $57,922.65 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Biocodex, INC. | $9,850.55 | 2021-2025 | Diacomit |
| Zogenix INC. | $7,325.99 | 2020-2021 | |
| Ucb Sa | $5,624.53 | 2025 | Fintepla |
| Acadia Pharmaceuticals INC | $3,879.62 | 2022-2024 | Daybue |
| Aquestive Therapeutics, INC. | $2,569.74 | 2019-2025 | |
| Otter Pharmaceuticals, LLC | $1,683.98 | 2024-2025 | Sympazan |
| Pyros Pharmaceuticals, INC. | $1,645.96 | 2023-2024 | Vigpoder |
| Neuropace, INC. | $550.28 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $524.19 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $429.74 | 2019-2022 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $369.48 | 2019-2025 | Qelbree, Qelbree |
| Amgen INC. | $161.36 | 2021-2023 | Enbrel |
| Takeda Pharmaceuticals U.S.A., INC. | $157.60 | 2019-2024 | Vpriv |
| Eisai INC. | $155.70 | 2021-2022 | |
| Neurelis, INC. | $154.78 | 2020-2025 | Valtoco |
| Nobelpharma America, LLC | $117.32 | 2022-2025 | |
| Biomarin Pharmaceutical INC. | $108.59 | 2022 | |
| Octapharma USA, INC. | $106.43 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Corium, LLC | $95.87 | 2022-2025 | Azstarys |
| Neos Therapeutics, Lp | $92.69 | 2019-2024 | Adzenys Xr-Odt |
| Immedica Pharma US, INC. | $84.27 | 2023-2024 | |
| Aucta Pharmaceuticals, INC. | $79.05 | 2024-2025 | Motpoly Xr |
| Tris Pharma INC | $75.19 | 2019-2025 | Dyanavel Xr |
| Biogen, INC. | $63.70 | 2019-2024 | Skyclarys |
| Csl Behring | $63.60 | 2025 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $62.79 | 2023-2025 | Fycompa |
| Shire North American Group INC | $52.88 | 2019 | |
| Vertical Pharmaceuticals, LLC | $52.87 | 2019-2025 | Relexxii |
| Intrabio INC | $49.22 | 2025 | Aqneursa |
| Sumitomo Pharma America, INC. | $41.86 | 2023-2024 | Aptiom |
| Aprecia Pharmaceuticals, LLC | $40.73 | 2019-2023 | Spritam |
| Ironshore Pharmaceuticals INC. | $35.13 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $33.67 | 2019-2023 | |
| Azurity Pharmaceuticals, INC. | $28.49 | 2025 | Zonisade |
| Itamar Medical INC | $21.21 | 2023 | Watchpatone |
| Genzyme Corporation | $17.96 | 2024 | |
| Alexion Pharmaceuticals, INC. | $17.77 | 2022 | |
| Saol Therapeutics INC. | $14.90 | 2019 | |
| Sarepta Therapeutics, INC. | $14.81 | 2024 | Elevidys |
| Amneal Pharmaceuticals LLC | $14.40 | 2019 | |
| Avion Pharmaceuticals | $14.21 | 2023 | Methylphenidate Hydrochloride |
| Genentech USA, INC. | $13.65 | 2023 | Actemra |
| Adlon Therapeutics L.P. | $13.39 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $13.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Keough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.